CN110545836A - 用载脂蛋白模拟物治疗与年龄有关的黄斑变性和其他眼部疾病 - Google Patents

用载脂蛋白模拟物治疗与年龄有关的黄斑变性和其他眼部疾病 Download PDF

Info

Publication number
CN110545836A
CN110545836A CN201780087274.0A CN201780087274A CN110545836A CN 110545836 A CN110545836 A CN 110545836A CN 201780087274 A CN201780087274 A CN 201780087274A CN 110545836 A CN110545836 A CN 110545836A
Authority
CN
China
Prior art keywords
mimetic
administered
months
apo
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780087274.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·鲁道夫
K·罗伊兹曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mark Reagan Ltd
Original Assignee
Mark Reagan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark Reagan Ltd filed Critical Mark Reagan Ltd
Publication of CN110545836A publication Critical patent/CN110545836A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201780087274.0A 2017-01-24 2017-01-24 用载脂蛋白模拟物治疗与年龄有关的黄斑变性和其他眼部疾病 Pending CN110545836A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/014754 WO2018139991A1 (en) 2017-01-24 2017-01-24 Treatment of age-related degeneration and other eye diseases with apolipoprotein mimetics

Publications (1)

Publication Number Publication Date
CN110545836A true CN110545836A (zh) 2019-12-06

Family

ID=57966185

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780087274.0A Pending CN110545836A (zh) 2017-01-24 2017-01-24 用载脂蛋白模拟物治疗与年龄有关的黄斑变性和其他眼部疾病

Country Status (5)

Country Link
EP (1) EP3554531A1 (ko)
JP (1) JP2020514407A (ko)
KR (1) KR20190124704A (ko)
CN (1) CN110545836A (ko)
WO (1) WO2018139991A1 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111494354A (zh) * 2020-04-21 2020-08-07 复旦大学附属眼耳鼻喉科医院 Abca1激动剂在制备治疗眼部疾病的药物中的用途
CN113842385A (zh) * 2021-10-26 2021-12-28 南京北极光生物科技有限公司 一种降低视网膜黄斑变性的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
EP3843721A4 (en) * 2018-08-29 2022-10-12 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHODS OF USE
AU2019378845A1 (en) * 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
AU2019419468A1 (en) * 2019-01-04 2021-07-15 The Regents Of The University Of California Compositions and methods for promoting angiogenesis in the eye
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021144476A1 (en) 2020-02-18 2021-07-22 Novo Nordisk A/S Pharmaceutical formulations
WO2023194797A1 (en) * 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2024114641A1 (en) * 2022-11-28 2024-06-06 Shenzhen Oculgen Biomedical Technology Co., Ltd C5/vegf bispecific binding molecules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280500A (zh) * 1997-09-29 2001-01-17 琼-路易斯·达索克斯 载脂蛋白a－i激动剂及其在异常脂血相关病症的治疗中的应用
US20040266663A1 (en) * 2001-12-07 2004-12-30 Schwartz Daniel M. Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and bruch's membrane (BM)
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
US20100143444A1 (en) * 2000-08-24 2010-06-10 Anantharamaiah Gattadahalli M Peptides and peptide mimetics to treat pathologies associated with eye disease
WO2016018665A1 (en) * 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1292721C (zh) 1999-10-21 2007-01-03 爱尔康公司 药物释放装置
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
KR102512178B1 (ko) 2011-05-18 2023-03-20 메더리스 다이어비티즈, 엘엘씨 개선된 펩티드 제약
CN117903257A (zh) 2012-11-20 2024-04-19 梅德瑞斯糖尿病有限责任公司 用于胰岛素抗性的改良的肽药物
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280500A (zh) * 1997-09-29 2001-01-17 琼-路易斯·达索克斯 载脂蛋白a－i激动剂及其在异常脂血相关病症的治疗中的应用
US20100143444A1 (en) * 2000-08-24 2010-06-10 Anantharamaiah Gattadahalli M Peptides and peptide mimetics to treat pathologies associated with eye disease
US20040266663A1 (en) * 2001-12-07 2004-12-30 Schwartz Daniel M. Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and bruch's membrane (BM)
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2016018665A1 (en) * 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAPSTONE THERAPEUTICS，: "Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering", 《CAPSTONE THERAPEUTICS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111494354A (zh) * 2020-04-21 2020-08-07 复旦大学附属眼耳鼻喉科医院 Abca1激动剂在制备治疗眼部疾病的药物中的用途
CN111494354B (zh) * 2020-04-21 2021-06-22 复旦大学附属眼耳鼻喉科医院 Abca1激动剂在制备治疗眼部疾病的药物中的用途
CN113842385A (zh) * 2021-10-26 2021-12-28 南京北极光生物科技有限公司 一种降低视网膜黄斑变性的方法

Also Published As

Publication number Publication date
JP2020514407A (ja) 2020-05-21
EP3554531A1 (en) 2019-10-23
WO2018139991A1 (en) 2018-08-02
KR20190124704A (ko) 2019-11-05

Similar Documents

Publication Publication Date Title
US20210085797A1 (en) Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
CN110545836A (zh) 用载脂蛋白模拟物治疗与年龄有关的黄斑变性和其他眼部疾病
US20180296525A1 (en) Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
US20210138034A1 (en) Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
JP2020528082A5 (ko)
AU2009240470B8 (en) Inhibition of neovascularization by cerium oxide nanoparticles
Taskintuna et al. Update on clinical trials in dry age-related macular degeneration
JP2019034947A (ja) 眼疾患を予防または治療するための方法および組成物
Gil-Martínez et al. Pharmacological advances in the treatment of age-related macular degeneration
US20190225660A1 (en) Method of treating and preventing ocular angiogenesis
WO2011097577A2 (en) Compositions and methods for treating or preventing retinal degeneration
JP2007224030A (ja) 黄斑変性および関連する眼の症状の治療方法
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
US20200188405A1 (en) Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
Sapra et al. Eye in metabolic disorders: Manifestations and drug delivery systems
Comer et al. Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration
Buratto et al. Cystoid Macular Edema Following Cataract Surgery
JP2023550458A (ja) 眼性疾患を治療する方法における使用のためのｖｅｇｆアンタゴニスト
Yehoshua et al. Treatment approaches for dry AMD
US20180177805A1 (en) Intravitreal Lysine Acetylsalicylate As Treatment For Diabetic Retinopathy
Koul et al. Recent Advances in the Management of Age-Related Macular Degeneration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011780

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191206